Cutaneous Melanoma

Bibliographic Information

Other Title
  • BNCTの臨床:皮膚悪性黒色腫
  • BNCT ノ リンショウ : ヒフ アクセイ コクショク シュ

Search this article

Abstract

The study of boron neutron capture therapy(BNCT) for malignant melanoma was initiated by Y. Mishima and his associates. Following basic research of 13 years, this team started the first clinical trial of cutaneous melanoma BNCT using 10B-para-boronophenylalanine(BPA) in 1985. Since then, 32 patients have been treated. We developed the following regimen for BNCT of malignant melanoma:1) 170 - 250 mg/kg of BPA-fructose complex is administered by drip infusion over 3-hours. 2) The minimum dose for melanoma control by single irradiation is assumed to be 25Gy-eq. 3) The maximum tolerable dose to the skin by single irradiation is assumed to be 18Gy-eq. 4) As the therapeutic dose, the maximum tolerable dose to the skin itself is chosen. We report the clinical results of two patients with cutaneous melanoma treated by BNCT. We believe that cutaneous melanoma are suitable for BNCT and that the excellent results will have a great impact on patients in QOL.

Journal

  • RADIOISOTOPES

    RADIOISOTOPES 64 (1), 115-121, 2015

    Japan Radioisotope Association

References(8)*help

See more

Related Projects

See more

Details 詳細情報について

Report a problem

Back to top